LENZ Therapeutics (LENZ) Stock Price, News & Analysis

Company Overview

LENZ Therapeutics is a biopharmaceutical company focused on developing treatments for presbyopia, the age-related difficulty focusing on nearby objects. Its lead product, VIZZ (aceclidine ophthalmic solution), is a prescription eye drop approved in the United States for treating presbyopia in adults.

VIZZ is designed to improve near vision by constricting the pupil, which can increase depth of focus. The company’s work centers on developing and commercializing this topical, non-invasive treatment as an alternative to corrective eyewear for people with presbyopia.

LENZ became a publicly traded company in 2024 following a merger with Graphite Bio. Its business is focused on the U.S. market for presbyopia treatments.

Key Stats

• Today's Range: $3.91 to $4.17
• 50-Day Range: $3.01 to $5.96
• 52-Week Range: $2.80 to $32.13
• Volume: 748,571 shs
• Average Volume: 1.23 million shs
• Market Capitalization: $129.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.75
• Consensus Rating: Hold

LENZ Therapeutics Stock Analysis - MarketRank™

LENZ Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 166th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

LENZ Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

LENZ Therapeutics has a consensus price target of $14.75, representing about 257.1% upside from its current price of $4.13.

Amount of Analyst Coverage

LENZ Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LENZ Therapeutics are expected to grow in the coming year, from ($4.08) to ($1.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LENZ Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENZ Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENZ Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

24.54% of the float of LENZ Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LENZ Therapeutics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in LENZ Therapeutics has recently decreased by 22.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENZ Therapeutics does not currently pay a dividend.

Dividend Growth

LENZ Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.05

News Sentiment

LENZ Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LENZ Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,134,778.00 in company stock.

Percentage Held by Insiders

8.30% of the stock of LENZ Therapeutics is held by insiders.

Percentage Held by Institutions

54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/28/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LENZ
• Previous Symbol: NASDAQ:LENZ
• CIK: 1815776
• Web: www.lenz-tx.com
• Phone: (858) 925-7000
• Fax: N/A
• Employees: 152
• Year Founded: 2013

Price Target and Rating

• Average Price Target for LENZ Therapeutics: $14.75
• High Price Target: $29.00
• Low Price Target: $5.00
• Potential Upside/Downside: +257.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.13 million
• Net Margins: -1,134.97%
• Pretax Margin: -1,134.93%
• Return on Equity: -59.56%
• Return on Assets: -54.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.66
• Quick Ratio: 11.39

Sales & Book Value

• Annual Sales: $19.09 million
• Price / Sales: 6.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.11 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 31,420,000
• Free Float: 28,813,000
• Market Cap: $129.76 million
• Optionable: Optionable
• Beta: 0.78